Status:Stopped Early
Principal Investigator(s):Glenda Gray, M.D.; James Kublin, MD, MPH
Objective:Designed to evaluate the safety and preliminary efficacy of a Merck HIV candidate vaccine (same as tested in the STEP study) but conducted in South Africa
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionThree doses of MRKAd5 HIV-1 gag/pol/nef vaccine
Mode of DeliveryIntramuscular
Trial Sponsors: HVTN, NIAID
Start Date
End Date
January 31, 2007
August 31, 2012
Age range: 18 Years ↔ 55 Years
Population:Cisgender Men, Cisgender Women